Download Curriculum Vitae

CURRICULUM VITAE
JASON M. FOSTER M.D.
Business Address
University of Nebraska Medical Center
Department of Surgery
Division of Surgical Oncology
Associate Professor
984030 Nebraska Medical Center
Work: (402)559-7272; Fax: (402) 559-7900
Email: [email protected]
Education
1990-1994
Temple University School of Medicine – Philadelphia, PA 19140
Doctor of Medicine
1986-1990
Bucknell University – Lewisburg, PA 17837
BS, Chemistry
Internship/Residency
2001-2002
Chief Resident: Case Western Reserve University/University
Hospital of Cleveland, Cleveland, OH.
1994-2002
General Surgery: Case Western Reserve University/University
Hospital of Cleveland, Cleveland, OH
Fellowship
2004-2005
Gastrointestinal & Mixed Tumor Oncology: Roswell Park
Cancer Institute, Buffalo, NY
2002-2004
Surgical Oncology: Roswell Park Cancer Institute, Buffalo, NY
1996-1999
Allen Scholar Basic Science Research Fellowship: Case
Western Reserve University/University Hospital, Cleveland, OH
2
Academic Appointments
2010-present
Associate Professor of Surgery: Department of Surgical
Oncology, University of Nebraska Medical Center, Omaha,
NE
2010-present
Adjunct Associate Professor of Surgery: Department of
Surgical Oncology, Creighton University, Omaha, NE
2006-2010
Assistant Professor of Surgery: Department of
Surgical Oncology, Creighton University, Omaha, NE
2002-2006
Clinical Instructor: Department of Surgery, State University
of New York at Buffalo, Buffalo, NY
2000-2002
Affiliate Clinical Instructor: Department of Surgery,
Case Western Reserve University, Cleveland, OH
1996-2000
Adjunct Clinical Instructor: Department of Surgery,
Case Western Reserve University, Cleveland OH
Other Employment History
2002-present
Fellow: Department of Surgical Oncology, Roswell Park
Cancer Institute, Buffalo, NY
1997-1999
Surgical Staff: Department of Surgery, SUMMA Health
Systems, Akron, OH
1996-1999
Flight Surgeon: Department of Surgery, Metrohealth
Medical Center/ Case Western Reserve University,
Cleveland, OH
1994-2002
Resident: Department of General Surgery, Case Western
Reserve University/ University Hospitals of Cleveland,
Cleveland, OH
1987-1989
Summer Internship (Chemist): Mobay Chemical
Corporation, Pittsburgh, PA
Board Certification and State Licensures
2004-current
2/9/2024 1996-2005
2002-current
2005-current
American Board of Surgery: 48798 Exp:
Ohio: 35-07-1662-F
New York: 225358-1
Exp: 5/31/2007
Nebraska: 23497
Exp:
10/1/2014 USMLE I,II,III
6/92,9/93,6/95
3
Special Training
2003
2002-2003
2002-2003
techniques 2010
2013
Sentinel Lymph Node Technique
Interventional Endoscopy
Radiofrequency Ablation
Single Site Laparoscopic Surgery
Robotic Surgery Training
Awards and Honors
2008-2015
2008
1999
1998-1999
Grant 1996-1998
1996-1999
1997
1995
1990
Patient’s Choice Award Physicians
CUMC Hospital Promising Young Physician
Outstanding Young Americans
NIH K-12 Translation Research Oncology Research
NIH K-12 Research Oncology Training Grant
Dudley P. Allen Scholar Fellow, CWRU Dept. of Surgery
2nd place Abstract/Presentation at 36th Annual Cleveland
Surgical Society
Invitation to AACR Molecular Biology Workshop
Temple University Scholars Physiology
Scientific and Medical Societies
2006
2005
2003
2002
2001
2000
1995
1990
2004
2010
2010
2012
North Central Cancer Treatment Group
Creighton Medical Society
American Society of Clinical Oncology
Society of Surgical Oncology
American College of Surgeons
American Medical Association
American Association for Cancer Research
Student National Medical Association
National Medical Association
Southwestern Surgical
Association for Academic Surgery
Fellow of American College of Surgeons
Committees and Organizations
2008-current
2008-2010
My Sister’s Keeper Breast Cancer Survivors Board of Directors
Creighton University Colorectal Community Task Force for
Screening and Prevention
2007-2010
Creighton University Medical School Education Environment
Task Force Committee
2007-2010
Creighton Hospital Pharmacy & Therapeutics
Anticoagulation Committee
2006-2008
Creighton University Committee on Cancer
1998-1999
Association of Residents and Fellows
President 1998-1999 Graduate Medical Education Council Delegate
1998-2000
SNMA hospital delegate
1997-1999
Minority House Staff Organization Co-president
1997-1998
CWRU Advanced anatomy instructor for 4th year students
4
Clinical Interests
Gastrointestinal malignancies – pancreas, biliary, gastric, metastatic liver, CRC
Peritoneal metastasis
Hyperthermic therapy – HIPEC and ILP/ILI
Minimal Invasive GI surgery.
Melanoma, Sarcoma & GIST tumor
Current Research Interests
Discovery of Prognostic Factors and Therapeutic Targets in Malignant Peritoneal
Mesothelioma through the Identification of Gene Mutations and Molecular
Pathway Perturbations
Biological events and molecular signature of EGFR mutations in malignant
mesothelioma cancer cells
Efficacy of EGFR-TK inhibitors in mesothelioma tumors with and without EGFR
mutations
Investigation of the biological mechanism of tumor maintenance in colorectal
tumors with overexpression of mucin glycoproteins (MUC-1, MUC-2)
Role of hyperthermia in cancer therapy
Current IRB Approved Investigations:
1.
#298-12-EP: Monitoring of Cerebral Saturation During Cytoreductive
Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) –
Co-PI
2.
#647-12-EP: Investigation of outcome of patient with peritoneal metastasis
treated with CRS/HIPEC. Principal Investigator
3.
#646-12-EP: Confirmation of the safety of epidural anesthesia and catheter
use in patients receiving Dextran VTE prophylaxis. Principal Investigator
4.
#709-13-EP: Identification of Genes, Pathways, and Mutations Active in
Peritoneal Metastasis. Principal Investigator
5.
#287-12-EP: Prospective neo-adjuvant REGISTRY trial linking
MammaPrint, Subtyping and treatment response: Neoadjuvant Breast Registry
- Symphony Trial (NBRST) (pronounced “in breast”). Participant
6.
Submitted 2015: Clinical and genetic characterizations of hereditary cancer
Principal Investigator
Clinical Trials & Registry Trial
Active:
2
1. #253-13-EP: Integrated Cancer Repository for Cancer Research (iCaRe ) GI
& Abdominal Cancer Registry (GACC). Principal Investigator 2013
5
2. #253-13-EP: Integrated Cancer Repository for Cancer Researcyh (iCaRe2)
Melanoma Cancer Registry (MeLCare). Co-Investigator 2016
Pending approval:
3. Peritoneal Metastasis & CRS/HIPEC tumor registry. Submitted February 2016
4. Phase II trial investigating HIPEC & peritoneal lavage in cytologically positive
gastric cancer. In process
Research Funding/Grants/Donations
2014-current
$100,000
Mrs. Bobbye C. Hill Cancer Research Fund
University of Nebraska Foundation
2012-current
$42,000
Jonathan Platon Cancer Research Fund
University of Nebraska Foundation
2006-2009
$225,000
Health Futures Foundations Grant
Creighton University/State of Nebraska
2006-2010
$75,000
Center of Excellence Grant
Creighton University
2007-2009
$200,000
LB595
Creighton University/State of Nebraska
Research Project
1996-1999
Investigation of the autocrine and paracrine biological effects of
growth factor TGFβ perturbations in colon cancer that facilitate
and inhibit tumor progression
Principal Investigator: J. K. V. Willson M.D.
Ireland Cancer Center, Case Western Reserve University
1996-1999
Investigation of the autocrine and paracrine biological effects
of TGFα up-regulation that facilitates colon cancer progression
Principal Investigator: J. K. V. Willson M.D.
Ireland Cancer Center, Case Western Reserve University
1991-1993
Role of free radicals in ischemic brain injury and the
protective effects of antioxidants
Preceptor: Ron Tuma PhD.
Temple University School of Medicine
1990-1993
Role of neutrophils in the exacerbation of cerebral ischemia
and the protective effects of neutropenia
Preceptor: Ron Tuma PhD.
Temple University School of Medicine
6
Publications: Peer Reviewed
1. Jaing, D, Yang H, Willson JKV, Liang J, Humphrey LE, Zborowska E, Wang
D, Foster J, Fan R, Brattain MG. Autocrine Transforming Growth Factor α
Provides a Growth Advantage to Malignant Cells by Facilitating Re-entry into
the Cell Cycle from Suboptimal Growth States, 1998, J Biol Chem 273,
31471-9.
2. Ye SC, Foster JM*, Li WH, Liang JR, Zborowska E, Venkateswarlu S, Gong
JG, Brattain MG, Willson JKV. Contextual Effects of TGFβ on the
Tumorigenicity of Human Colon Carcinoma. 1999, Cancer Res 59,
4725-31.
3. Hurd TC, James T, Foster JM*. Factors Affecting Breast Cancer Treatment:
Underserved and Minority Populations. 2005, Surg Oncol Clin North Am
14(1), 119-30.
4. Palesty JA, Foster JM*, Hurd TC, Watroba N, Rezaishiraz H, Edge SB.
Axillary Recurrence in Women with a Negative Sentinel Lymph Node and No
Axillary Dissection in Breast Cancer. 2006, J Surg Oncol 93, 129-32
5. Foster JM, Integan M, Litwin A, Kuvshinoff B, Gibbs JF. The utilization of
laparoscopy to diagnose regenerative nodular hyperplasia, the “great
masquerader” of liver tumors. 2006, J Gastrointest Surg 10(5), 727-33
6. Javle M, Yu J, Khoury T, Chadha K, Iyer RV, Kuvshinoff B, Gibbs JG,
Geradts J, Foster JM, Black J, Brattain M. Akt expression may predict
favorable prognosis in cholangiocarcinoma. 2006, J Gastroenterol
Hepatol 21, 1744-51
7. J. Esquivel, R. Sticca, P. Sugarbaker, E. Levine, T.D. Yan and The Peritoneal
Surface Malignancy Group: Foster J et al Cytoreductive Surgery and
Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal
Surface Malignancies of Colonic Origin: A Consensus Statement. 2006, Ann
Surg Onc 14(1), 128-33
8. Foster JM, Hoshi H, Chu Q, Smith JL, Driscoll D, Nava HR, Gibbs JF.
Radical re-resection is indicated for all T2 and T3 gallbladder and results in
the same survival as primarily resected gallbladder cancers. 2006, Ann Surg
Onc 14(2), 833-40
9. Rajput A, Koterba AP, Kreiserg JI, Foster JM, Willson JKV, Brattain M. A
novel EGFR antagonism in vivo. 2007, Cancer Res. Jan 15;67(2):665-73
10. Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF.
Cox-2 expression and EGFR expression with downstream pathway activation
are prognostic predictors in hepatocellular carcinoma and are potential targets
for biological therapies. 2007, Ann Surg Oncol. Feb;14(2):752-8. Epub 2006
Dec 5
11. Foster JM, Filacoma P, Brady, W, Nava H, Hicks W, Rigual N, Smith J,
Loree T, Gibbs JF. The ‘Push’ technique is a safe method for placing
percutaneous endoscopic gastrostomy tubes in head and neck cancer patients.
2007, Surg Endosc. Jun;21(6):897-901. Epub 2006 Dec 16
12. Gatalica Z, Foster JM, Loggie BW. HPV associated pseudomyxoma
peritonei. Croat Med J. 2008 Oct;49(5):669-73.
13. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and
existing mutations in the EGF receptor tyrosine kinase domain are predictors
of optimal resectability in malignant peritoneal mesothelioma. Ann Surg
Oncol. 2009 Jan;16(1):152-8. Epub 2008 Nov 8
7
14. Lynch H, Steve Lanspa S, Sharma P. Gatalica Z, Foster JM. FAP, Gastric
Cancer, and Genetic Counseling Featuring Children and Young Adults: A
Family Study and Review. Fam Cancer 2010 Dec;9(4):581-8.
15. Foster JM, Uppala R, Carreau JH, Gatalica, Z, Lilleberg S, Loggie, BW.
Novel and existing functional mutations in the EGF receptor tyrosine kinase
domain are predictors of outcome in malignant peritoneal mesothelioma.
World J Surg Oncol. 2010 Oct 13;8:88.
16. Gupta PK, Turaga KK, Gupta H, Miller WJ, Loggie BW, Foster JM.
Determinants of Outcomes in Pancreatic Surgery and Related Use of Hospital
Resources. J Surg Oncol 2011 Nov 1;104(6):634-40.
17. Gupta PK*, Carreau J*, Loggie, BW, Grotz TE, Gatalica, Z, Sharma P, Foster
JM. Routine right hemicolectomy (RHC) may not be indicated in
pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Am
Surg 2012 Feb;78(2):171-72011.
18. Turaga K, Levine E, Barone R, Sticca R and The Peritoneal Surface
Malignancy Group: Foster J et al Consensus guidelines from the ASPSM on
the standardization of the delivery of HIPEC in colorectal cancer patients in
the US, Ann Surg Onc 2014 May;21(5):1501-5.
19. Dhir M, Crocket D, Stevens TM, Silberstein P, Hunter W, Foster JM,
Efficacy of Neoadjuvant Imatinib in the treatment of unresectable metastatic
dermatofibrosarcoma protuberans. Clin Sarcoma Res J August 2014 4-8.
20. Foster JM , Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Patel A.
The efficacy of Dextran-40 as a VTE prophylaxis option in CRS/HIPEC
surgery. Submitted J Surg Oncol 2015
21. Foster JM, Sleightholm RL, Smith L, Ceelen W, Deraco M, Yildrim Y,
Levine E, Munoz C, Ghehen O, Patel A, Esquivel J. The American Society of
Peritoneal Surface Malignancies (ASPSM) Evaluation of Peritoneal Surface
Disease Score (PSDS) in 1.051 Advanced Ovarian Cancer undergoing CRSHIPEC and evaluation of PSDSS. Re-Submitted February 2016 Ann Surg
Oncol 2016
22. Foster JM, Grotz TE, Sleightholm RL, Gatalica, Z, Sharma P, Loggie BW.
Analysis of immunohistochemical predictors of outcome in pseudomyxoma
peritonei. Resubmitted J Surg Oncol 2016
23. Foster JM , Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Patel A.
The efficacy of Dextran-40 as a VTE prophylaxis option in CRS/HIPEC surgery.
Submitted Am Surg 2016
24. Foster JM, Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S. Early
identification of DPAM in ‘at risk’ MAN patients a new approach to MAN
surveillance. Submitted Am Surg 2016
25. El,-Abaseri T, Loggie BW, Foster JM. Novel illustration that MUC-2
over- expression promotes tumor growth by autocrine cellular events and signaling.
Submitted J Surg Oncol 201
26. Wilcockson J, Sleightholm RL, Foster JM, Durden FL. Surgical management of
metastatic basal cell carcinoma. Submitted J Plast Reconstr Surg 2015
27. Sleightholm RL, Hardie V, Nicholas T, Watley D, Broekhuis J, Wahlmeier S,
Foster JM. Defining the safety of epidural pain control in CRS/HIPEC
In conjunction with VTE prophylaxis. In preparation J Anesth 2016
28. Broekhuis J, Sleightholm RL, Watley D, Wahlmeier S, Foster JM. Safety and
outcomes of cytoreductive surgery and HIPEC in elderly patients with high PCI
large volume peritoneal metastasis. In preparation J Surg Oncol 2016
8
29. Watley D, Sleightholm RL, Broekhuis J, Foster JM. HIPEC outcomes in OEC at
index surgery, salvage, and palliative CRS/HIPEC. In preparation World J
Surg Oncol
30. Chadha KS, Thatikonda C, Schiff M, Miller A, Foster JM, Nava H, Sitrin MD.
Outcomes of Percutaneous Endoscopic Gastrostomy Tube Placement using the
Brown-Muller T-fastener technique in Head and Neck and Esophageal Cancer
Patients. In preparation J Parent Ent Nut
Publications: Book Chapters
1. Yi, B, Foster JM, Loggie BW. Hyperthermic Intraperitoneal Chemotherapy
in Nongynecologic Cancer. Current Clinical Oncology: Intra-peritoneal
Cancer Therapy. 2007
2. Foster JM, Nava H, Hicks W, Gibbs J, Indications for pre- or peripercutaneous endoscopic gastrostomy tubes (PEG) and predictors of
prolonged enteral feeding in head and neck cancer patients treated
with surgical extirpiration. InTech: Gastrotomy. 2011
Publications in development
Patel A; Batra S; Cushman-Volkoun A; Foster JM. Identifying glycoprotein
signatures in peritoneal metastasis.
Cushman-Volkoun A; Batra S; Foster JM. Identifying gene mutation and gene
expression in peritoneal metastasis.
Sleightholm RA; Patel A; Bodkin T; Burke A; Foster JM. Home Start Parental
Nutrition Therapy is safe, cost effective strategy improving outcomes and reduces
admissions/readmissions
Burt JJ; Sleightholm RA; Patel A; Eastman S; Foster JM. The development of a
RediVac (ambulatory wound vac therapy) improves outcomes and reduces cost and
readmission.
Published Abstracts and Presentations
1. Foster JM, Willis J, Brattain MG, Willson JKV. TGFα overexpression
results in in vivo progression of colon cancer cells. 36th Annual Cleveland
Surgical Society 1998
2. Foster JM, Willis J, Brattain MG, Willson JKV. TGFα overexpression
results in in vivo progression of weakly tumorigenic human colon cancer cells.
Digestive Disease Week (DDW) 1998
3. Foster JM, Willis J, Venkaeswarlu S, Lin Y, Ferguson K, Zboroskwa E,
Brattain MG, Willson JKV. Ectopic TGFα expression in colon non-tumorigenic
cancer cells results in in vivo progression by induction of angiogenesis,
proliferation and the inhibition of apoptosis. 90th Annual AACR Meeting 1999
4. Hoshi H, Foster JM, Chu Q, Kuvshinoff B, Rajput A, Driscoll D, Nava HR,
Gibbs JF. Radical re-resection is indicated for all T2 and T3 gallbladder and
results in the same survival as primarily resected gallbladder cancers. SSO 2004
9
5. Foster JM, Hoshi H, Chu Q, Kuvshinoff B, Rajput A, Driscoll D, Nava HR,
Gibbs JF. Radical re-resection is indicated for all T2 and T3 gallbladder and
results in the same survival as primarily resected gallbladder cancers. Winter
Gastrointestinal American of Clinical Oncology (ASCO-GI) 2005
6. Foster JM, Black J, LeVea C, Kuvshinoff B, Gibbs JF, Javle M. COX-2 and
EGFR expression are common in hepatocellular carcinoma supporting biological
targeted therapy directed at these pathways. Winter ASCO-GI 2005
7. Palesty JA, Foster JM, Kraybill WG, Banka T, Sheldon DG, Driscoll D, Kane
JM. Melanoma patients and incidence of non-melanoma malignancies. SSO
2005
8. Rajput A, Wang J, Foster JM, Dawson D, Willis J, Brattain M, Wilson JKV.
The role of autocrine transforming growth factor alpha in epidermal growth factor
receptor mediated tumorigenicity. Society of University Surgeons 2006
9. Foster JM, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF.
Cox-2 expression and EGFR expression with downstream pathway activation are
prognostic predictors in hepatocellular carcinoma and are potential targets for
biological therapies. Winter ASCO-GI 2006
10. Foster JM, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF.
Cox-2 expression and EGFR expression with downstream pathway activation are
prognostic predictors in hepatocellular carcinoma and are potential targets for
biological therapies. Oral Plenary Session III SSO 2006
11. Foster JM, Filacoma P, Brady B, Nava H, Hill H, Hicks W, Rigual N,
Loree T, Gibbs JF. Defining the indications for prophylactic percutaneous
endoscopic gastrostomy tubes in head and neck cancer patients. SSO 2006
12. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and
existing mutations in the EGF receptor tyrosine kinase domain are predictors of
optimal resectability (OR) in malignant peritoneal mesothelioma (MPM). Winter
ASCO-GI 2007
13. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and
existing mutations in the EGF receptor tyrosine kinase domain are predictors of
optimal resectability (OR) in malignant peritoneal mesothelioma (MPM). Oral
Session Second International Symposium on Regional Cancer Therapies. 2007
14. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and
existing mutations in the EGF receptor tyrosine kinase domain are predictors of
optimal resectability (OR) in malignant peritoneal mesothelioma (MPM). Oral
Session SSO 2007
15. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and
existing mutations in the EGF receptor tyrosine kinase domain are predictors of
optimal resectability (OR) in malignant peritoneal mesothelioma (MPM). Oral
(Discussion) Session ASCO 2007
16. Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW.
Analysis of immunohistochemical predictors of outcome in pseudomyxoma
peritonei. Winter ASCO-GI 2008
17. Foster JM, El,-Abaseri T, Loggie BW. Novel illustration that MUC-2 overexpression promotes tumor growth by autocrine cellular events and signaling.
Winter ASCO-GI 2008
10
18. Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW.
Analysis of immunohistochemical predictors of outcome in pseudomyxoma
peritonei. Oral Session Third International Symposium on Regional Cancer
Therapies. 2008
19. Foster JM, El,-Abaseri T, Loggie BW. Novel illustration that MUC-2 overexpression promotes tumor growth by autocrine cellular events and signaling.
Oral Session Third International Symposium on Regional Cancer Therapies.
2008
20. Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW.
Analysis of immunohistochemical predictors of outcome in pseudomyxoma
peritonei. SSO 2008
21. El,-Abaseri T, Foster JM, Loggie BW. MUC-2 over-expression promotes
tumor growth by autocrine cellular events and signaling. AACR 2008
22. Foster JM, Gupta P, Carreau J, Grotz TE, Gatalica, Z, Sharma P, Loggie,
BW. Routine right hemicolectomy (RHC) may not be indicated in
pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Winter
ASCO-GI 2009
23. Foster JM, El-Abaseri T, Loggie BW. MUC-2 overexpression in colorectal
cancer promotes tumor survival by regulation of Caspase-8 and Akt expression.
Winter ASCO-GI 2009
24. Foster JM, Uppala P, Govindarajan V, Carreau J, Gatalica, Z, Lillleberg S,
Nath S, Loggie BW. Novel and existing activating EGFR mutations are predictive
of a ‘relative’ improved survival in malignant peritoneal mesothelioma (MPM)
and responsive to EGFR-TK inhibitors (EGFR-TKI). Oral Session Fourth
International Symposium on Regional Cancer Therapies. 2009
25. Foster JM, Gupta P, Carreau J, Grotz TE, Gatalica, Z, Sharma P, Loggie,
BW. Routine right hemicolectomy (RHC) may not be indicated in
pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Oral
Session Fourth International Symposium on Regional Cancer Therapies. 2009
26. Foster JM, El-Abaseri T, Loggie BW. MUC-2 overexpression in colorectal
cancer promotes tumor survival by regulation of Caspase-8 and Akt expression.
SSO 2009
27. Lilleberg SL, Foster JM, Uppala R, Govindarajan V, Gatalica Z, Loggie
BW. Malignant Peritoneal Mesotheliomas Harbor Somatic Mutations in EGFR,
MET, and several Gate-Keeper Genes: Potential Predictive and Prognostic
Markers for Focused Treatment Strategies. SSO 2009
28. Lilleberg SL, Foster JM, Uppala R, Govindarajan V, Gatalica Z, Loggie
BW. Malignant Peritoneal Mesotheliomas Harbor Somatic Mutations in EGFR,
MET, and several Gate-Keeper Genes: Potential Predictive and Prognostic
Markers for Focused Treatment Strategies. AACR 2009
29. Lilleberg SL, Foster JM, Uppala R, Govindarajan V, Gatalica Z, Loggie
BW. Analysis of Pseudomyxoma Peritonei and Appendiceal Adenocarcinomas
reveal Somatic Mutations of Key Genes within the MAPK, AKT, and WNT
Signaling Pathways: Potential Prognostic and Predictive Markers for Focused
Treatment Strategies. AACR 2009
30. Foster JM, Uppala P, Govindarajan V, Carreau J, Gatalica, Z, Lillleberg S,
Nath S, Loggie BW. Novel and existing activating EGFR mutations are predictive
11
of a ‘relative’ improved survival in malignant peritoneal mesothelioma (MPM)
and responsive to EGFR-TK inhibitors (EGFR-TKI). Oral (Discussion) Session
ASCO 2009
31. Foster JM, Gupta P, Blas JT, Carreau J, Grotz TE, Loggie, BW. Venous
thromboembolism prophylaxis with Sequential compression devices, Early
ambulation, and Dextran (SEED) is a safe, effective and easily reversible surgical
prophylaxis intervention in peritoneal carcinomatosis management. Winter
ASCO-GI 2010
32. Foster JM, Gupta P, Blas JT, Carreau J, Grotz TE, Loggie, BW. Venous
thromboembolism prophylaxis with Sequential compression devices, Early
ambulation, and Dextran (SEED) is a safe, effective and easily reversible surgical
prophylaxis intervention in peritoneal carcinomatosis management. Oral Session
5th International Symposium on Regional Cancer Therapies. 2010
33. Foster JM, Carreau J, Loggie BW. The utility of laparoscopy in early
Pseudomyxoma Pertonie (PMP). Oral Session 5th International Symposium on
Regional Cancer Therapies. 2010
34. El-Abaseri T, Thomas P, Loggie BW, Foster JM. MUC-2 overexpression in
colorectal cancer promotes tumor survival by regulation of Caspase-8 and akt
expression. MUC2 Oral Session 5th International Symposium on Regional
Cancer Therapies. 2010
35. Gupta P, Carreau J, Grotz TE, Gatalica, Z, Sharma P, Loggie, BW, Foster
JM. Routine right hemicolectomy (RHC) may not be indicated in
pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). South
Eastern Surgical Conference. 2010
36. Gupta P, Blas JT, Carreau J, Grotz TE, Loggie BW, Foster JM. Venous
thromboembolism prophylaxis with Sequential compression devices, Early
ambulation, and Dextran (SEED) is a safe, effective and easily reversible surgical
prophylaxis intervention in peritoneal carcinomatosis management. South Eastern
Surgical Conference. 2010
37. Gupta PK, Turaga KK, Gupta H, Miller WJ, Loggie BW, Foster JM.
Determinants of Resource Utilization In Pancreatoduodenectomy: A Multicenter
Analysis Of 1467 Patients. SSO 2010
38. Gupta PK, Gupta H, Turaga KK, Miller WJ, Loggie BW, Foster JM.
Predictors of Pulmonary and Cardiac Complications Following
Pancreatoduodenectomy for Cancer. SSO 2010
39. Foster JM, Uppala P, Govindarajan V, Carreau J, Gatalica, Z, Lillleberg S,
Nath S, Loggie BW. Novel and existing activating EGFR mutations are predictive
of a ‘relative’ improved survival in malignant peritoneal mesothelioma (MPM)
and responsive to EGFR-TK inhibitors (EGFR-TKI). Oral. 10th Annual
Mesothelioma Foundation meeting. 2010
40. Foster JM, Role of Neoadjuvant Chemotherapy in carcinomatosis arising
from high grade appendix adenocarcinoma. Oral Session Sixth International
Symposium on Regional Cancer Therapies. 2011
41. Bodkin T, Burke A, Skiedziel P, Tanner J, Foster JM. Collaboration
between Referring Providers and Home Infusion Company Clinicians can
Improve Outcomes and Avoid Hospital Admissions for Patients Requiring Home
Parenteral Nutrition and May Represent a Safe, More Cost Effective Strategy.
ASPEN Clinical Nutrition meeting 2012
12
42. El-Abaseri T, Brattain M, Howell G, Foster JM. Extracellular mucin MUC2 promotes colon cancer growth and transformation in non-mucinous and
mucinous cancer cells. Regional Cancer Therapies 2013
43. Foster JM, Subbiah SP, Commers J, Fahed R. Is CRS & HIPEC a safe and
effective palliative treatment strategy in patients with refractory symptomatic
peritoneal metastasis? Regional Cancer Therapies. 2013
44. Foster JM, Subbiah SP, Commers J, Fahed R. Outcomes of untreated Stage
IV Ovarian cancer patients treated with HIPEC and one case treated with
synchronous HIPEC/HITHOC. Regional Cancer Therapies. 2013
45. Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Foster JM. Defining
the safety of epidural pain control in CRS/HIPEC in conjunction with VTE
prophylaxis. . The American Physician Scientists Association (APSA) (poster).
2014- 2015
46. Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Foster JM. Defining
the safety of epidural pain control in CRS/HIPEC in conjunction with VTE
prophylaxis. Regional Cancer Therapies (poster). 2014- 2015
47. Watley D, Sleightholm RL, Broekhuis J, Foster JM. HIPEC outcomes in
OEC at index surgery, salvage, and palliative CRS/HIPEC. Regional Cancer
Therapies. Regional Cancer Therapies (oral). 2014- 2015
48. Foster JM, Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S. Early
identification of DPAM in ‘at risk’ MAN patients a new approach to MAN
surveillance. Regional Cancer Therapies (poster). 2014- 2015
49. Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Foster JM. Safety
and outcomes of cytoreductive surgery and HIPEC in elderly patients with high
PCI large volume peritoneal metastasis. Regional Cancer Therapies. 2014- 2015
50. Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Foster JM. Defining
the safety of epidural pain control in CRS/HIPEC in conjunction with VTE
prophylaxis. 2014- 2015
51. Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Foster JM. Defining
the safety of epidural pain control in CRS/HIPEC in conjunction with VTE
prophylaxis. SWSC Quick Shot Oral Presentation. 2014- 2015
52. Watley D, Sleightholm RL, Broekhuis J, Foster JM. HIPEC outcomes in
OEC at index surgery, salvage, and palliative SWSC Poster. CRS/HIPEC. 2014
53. Wahlmeier S, Sleightholm RL, Watley D, Broekhuis J, Foster JM. Early
identification of DPAM in ‘at risk’ MAN patients a new approach to MAN
surveillance. SWSC Poster. 2014- 2015
54. Broekhuis J, Sleightholm RL, Watley D, Wahlmeier S, Foster JM. Safety
and outcomes of cytoreductive surgery and HIPEC in elderly patients with high
PCI large volume peritoneal metastasis. SWSC Poster. 2014- 2015
55. Sleightholm RL, Watley D, Broekhuis J, Wahlmeier S, Foster JM. Defining
the safety of epidural pain control in CRS/HIPEC in conjunction with VTE
prophylaxis. Midwest Student Biomedical Research Forum. 2014- 2015
56. Watley D, Sleightholm RL, Broekhuis J, Foster JM. HIPEC outcomes in
OEC at index surgery, salvage, and palliative CRS/HIPEC. Midwest Student
Biomedical Research Forum. 2014- 2015
57. Wahlmeier S, Sleightholm RL, Watley D, Broekhuis J, Foster JM. Early
identification of DPAM in ‘at risk’ MAN patients a new approach to MAN
surveillance. Midwest Student Biomedical Research Forum. 2014- 2015
13
58. Broekhuis J, Sleightholm RL, Watley D, Wahlmeier S, Foster JM. Safety
and outcomes of cytoreductive surgery and HIPEC in elderly patients with high
PCI large volume peritoneal metastasis. Midwest Student Biomedical Research
Forum. 2014- 2015
59. Patel A, Sukhwinder Kaur, Yuri Sheinin, Batra S, Foster JM. Evaluation
of glycoprotein expression profiles in peritoneal metastases as a potential
therapeutic target. 2015-16
60. Patel A, Cushman-Vokoun A, Sleightholm RL, Foster JM. Exploration of
mutations in GI cancers with peritoneal metastasis. Regional Cancer Therapies
Oral 2015-16
61. Sleightholm RL, Burt J, Watley D, Wahlmeier S, Foster JM. Reducing
VTE event rates in complex abdominal cancer surgery: A retrospective, single
institute comparison of dextran vs. heparin. ASCO 2015-16
Editorial Board
2010-current Journal of Surgical Oncology
Invited 2015 Journal of Surgery and Operative Care
Ad Hoc Journal Reviewer
Cancer
Annals of Surgical Oncology
Journal of Surgical Oncology
European Journal of Cancer
European Journal of Surgical Oncology
World Journal of Surgical Oncology
Tumor Biology
Asian-Pacific Journal of Hematology & Oncology
Hernia Journal
Invited Lectures
1. Contextual Effects of TGFβ on the tumorigenicity of Human Colon
Carcinoma. Surgical Grand Rounds University Hospital of Cleveland, Case
Western Reserve University 1997
2. The role of TGFα in colon cancer tumorigenesis and progression. Surgical
Grand Rounds University Hospital of Cleveland, Case Western Reserve
University 1998
3. Management of function and non-functional neuroendocrine tumors of the
pancreas. Oncology Lecture Series MetroHealth Medical Center, Case
Western Reserve University 1999
4. Current management of congenital tracheal-esophageal fistulas. Pediatric
Grand Rounds Cleveland Clinic/MetroHealth Medical Center, Case Western
Reserve University 2000
5. Total Mesorectal Excision in the management rectal cancer is superior to
Conventional resection with radiation. Oncology Lecture series MetroHealth
Medical Center, Case Western Reserve University 2001
14
6. Current Management of Gallbladder: What have the past 50 years taught us?
Roswell Park Cancer Institute Surgical Grand Rounds 2003
7. The Role of Brachytherapy for sarcoma management. Roswell Park Cancer
Institute Medical & Surgical Oncology joint lecture series 2004
8. Surgical management of hepatic neuroendocrine disease in the new
millennium. Roswell Park Cancer Institute Surgical Grand Rounds 2004
9. Current Management of Gallbladder: What have the past 50 years taught us?
State University of Buffalo Department of Surgery 2004
10. Advances in Breast cancer that have revolutionized the management of the
disease. Fourth Annual Women Issues in the 21st Century sponsored by
Creighton University October 7, 2005
11. Innovations in Surgical Oncology—Hyperthermic Therapy. Creighton
University Department of Surgery Grand Rounds, June 12, 2006
12. Contemporary management of Melanoma & Sarcoma. Keynote Speaker at
Metro Omaha Coder’s Association (MOCA) Creighton University November
10, 2006
13. The prevention and management of Skin and Colon Cancer. Senior Partner
Seminar Creighton University January 27, 2007
14. Updates in Colorectal cancer detection and treatment. 2nd Annual: Surgical
Techniques for Primary Care Physicians, Creighton University February 9,
2007
15. Diagnosis and management of Gastric and Pancreatic Cancer. Senior Partner
Seminar Creighton University June 23rd, 2007
16. Diagnosis and management of melanoma and colorectal cancer. Offutt Air
Force base Family Practice Grand Rounds February 6th 2008
17. Translational Research in Surgical Oncology. Creighton University
Department of Surgery Grand Rounds, May 19th, 2008
18. The prevention and management of colorectal cancer. Creighton
Community Health Center Health Fair June 13th, 2008
19. Common Cancer in women: prevention, screening, and management.
Women’s Health Conference June 21, 2008
20. Contemporary screening strategies in oncology. Creighton Community
Health Center Health Seminar July 11, 2008
21. Translational Research: MUC-2 in PMP & EGFR mutations in
Mesothelioma. Creighton University Department of Surgery presentation to
visiting professor—Timothy R. Billiar MD July 21st, 2008
22. My Sister’s Keeper Annual Breast Cancer Survivor Banquet: Chaired Round
Table Discussion on Contemporary management of Breast Cancer October
2008
23. The current role of CRS/IPHC in the management of appendix and colorectal
peritoneal surface disease. UNMC 4th Annual Thoracic and GI Conference
September 30, 2009
24. Contemporary Management of Peritoneal Surface Malignancies- Part I
(Appendix & Colorectal cancer). UNMC Grand Rounds December 16,
2009
25. Introduction to Peritoneal Surface Malignancies. UNMC OR Staff Education
Conference March 17, 2010
26. Introduction to Peritoneal Surface Malignancies. UNMC ICU Staff
Education Conference April 7 & 8, 2010
15
27. Contemporary Management of Peritoneal Surface Malignancies- Part
(Appendix & Colorectal cancer). CUMC Grand Rounds April 17,
2010
28. Role of EGFR in Hepatocellular and Mesothelioma abdominal carcinomas. .
Department of Surgery Weekly Research Forum May 26 2010
29. Introduction to Peritoneal Surface Malignancies. UNMC OR Peri-operative
Staff Education Conference April 7 & 8, 2010
30. Introduction to Peritoneal Surface Malignancies. UNMC Oncology Nursing
Staff Education Conference April 7 & 8, 2010
31. Management of patients with Peritoneal Surface Malignancies. AORN
quarterly meeting Nebraska Chapter February 9, 2011
32. Management of patients with Peritoneal Surface Malignancies. Infuscience
home health education conference February 15 2011
33. Contemporary Management of Peritoneal surface malignancies. Ob-Gyn
Grand Rounds March 6, 2011
34. Innovations in management of peritoneal surface malignancies. Optum
Conference July 26th, 2011.
35. Peritoneal Surface Malignancies Ripe for Research. UNMC Pathology
Grand Rounds, March 3, 2012
36. Innovations in management of peritoneal surface malignancies. UNMC
Oncology Nursing Fellowship Education, March 5, 2012
37. Innovations in management of peritoneal surface malignancies. UNMC
Retired Physician Breakfast, April 11, 2012
38. Foraging the frontiers of peritoneal surface malignancies, Wisconsin Surgical
Club, May 14, 2012
39. Peritoneal Surface Malignancies from a ‘Peritonealist’s’ Perspective:
Optimization of management & opportunities for translational research.
University of Maryland Oncology Grand Rounds, Visit Professor June 25,
2012
40. The role of home health care in improving patient outcomes. Annual
Bioscrip National Meeting, Invited Speaker October 2, 2012
41. Homestart TPN -- Keeping patients out of the hospital with cost effective
HHS. Annual Infuscience/UNMC Transplant & Oncology Meeting, May 9,
2013
42. Innovations in the Management of PSM – CRS & HIPEC. UNMC Patient
Outreach & Development Lecture Series September 24, 2013
43. Regional Cancer Therapies in the Management of Metastasis—Another
Example of Personalized Therapy. Marshall University Surgery Grand
Rounds October 2, 2013.
44. Surgical Management of Appendiceal Tumors. 8th Annual UNMC Thoracic
& GI Oncology Conference October 4th, 2013
45. Era of Personalized Oncology. UNMC Medical Student Surgical Society
Interest group February 4, 2014
46. Regional Cancer Therapies in the Management of Metastasis—Another
Example of Personalized Therapy. The Nebraska State Assembly of the
Association of Surgical Technologist (NESA AST) Winter Assembly March
1, 2014.
47. Role of Adjuvant or Neoadjuvant Targeted Therapy in Peritoneal
Mesothelioma: Is it time to study this? International Symposium on
Malignant Mesothelioma March 7th 2014 (Invited)
16
48. Contemporary Management of Cutaneous Melanoma. UNMC Family
Medicine Grand Rounds. March 23, 2014.
49. Personalized Therapy in Advanced Malignancies: Indications and Utility of
Regional Surgical Therapies. UNMC 5-West Staff Education Conference
July 11, 2014.
50. Contemporary Management of Cutaneous Melanoma. UNMC Surgery Grand
Rounds. July 16, 2014.
51. Role of HIPEC in Peritoneal Mesothelioma Management. Panel Discussion
Leader, International Symposium on Malignant Mesothelioma, March 7,
2015, Invited.
52. Personalized Surgical Therapy in Advanced and Metastatic Cancer.
American Academy of Professional Coders—AAPC Quarterly Meeting, May
19, 2015.
53. Utilizing Cytoreductive Surgery in the Management of Colorectal Cancer.
10th Annual UNMC Thoracic & GI Oncology Conference, October 9, 2015.
54. Contemporary Management of Cutaneous Melanoma. UNMC Plastic
Surgery Grand Rounds, February 10, 2016.
55. Skin Cancer Diagnosis, Management and Coding. American Academy of
Professional Coders—AAPC Quarterly Meeting, March 15, 2016.
56. Personalized Surgical Therapy in Advanced and Metastatic Cancer. Nebraska
Association of Nurse Anesthetists (NANA), April 9, 2016.
57. Contemporary Management of Cutaneous Melanoma, Advances in Primary,
Nodal and Advance Disease, NANA, April 9, 2016.
58. Peritoneal Metastasis Management: A Field Rooted in Personalized Care &
Robust with Research Opportunities. UNMC Pathology and Microbiology
Grand Rounds, May 2016
59. ICU Management Considerations in Cytoreductive Surgery & HIPEC.
UNMC ICU Staff Education Conference, May 2016.
60. Topic to be determined. Leader, International Symposium on Malignant
Mesothelioma, May 20, 2016. Invited.
61. Peritoneal Metastasis Management: A Field Rooted in Personalized Care &
Robust with Research Opportunities including Advance Reconstruction.
UNMC, Plastic Surgery Grand Rounds, June 10, 2016.